ArticleInternational journal of clinical and experimental medicine2014
ICAM-1 +469 A/G polymorphism and cancer risk: a meta-analysis involving 9375 subjects.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of Polymorphisms in Intercellular Adhesion Molecule 1 (ICAM-1) Gene with Cancer Susceptibility: A Meta-Analysis of 14 Case-Control Studies.Medical science monitor : international medical journal of experimental and clinical research · 2016Pooled it
- Contribution of Genetic Polymorphisms of Inflammation Response Genes on Sporadic Colorectal Cancer Predisposition Risk in Malaysian Patients - A Case Control Study.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- Association of intercellular adhesion molecule-1 single nucleotide polymorphisms with hepatocellular carcinoma susceptibility and clinicopathologic development.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- The polymorphism (Gln261Arg) of 12-lipoxygenase and cancer risk: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Interleukin-6 genotypes and serum levels in Chinese Hui population.International journal of clinical and experimental medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe ICAM-1 +469 A/G polymorphism has been implicated in susceptibility to cancer, but the results were inconclusive. The present meta-analysis aimed to investigate the association between the ICAM-1 +469 A/G polymorphism and cancer risk.
methodsWe searched PubMed, Embase to identify studies that evaluated the association between the ICAM-1 +469 A/G polymorphism and cancer risk. Data were extracted and statistical analysis was performed by using the software Revman 5.1 and STATA 12.0.
resultsA total of 14 studies involving 9375 subjects were included. The results suggested that ICAM-1 +469 A/G polymorphism had no associated with cancer risk (OR=0.91, 95% CI: 0.76-1.08, P=0.27 for GG+AG vs. AA). Subgroup analysis by cancer type indicated the there was no associated between this polymorphism and breast cancer (OR=0.91, 95% CI: 0.72-1.15, P=0.43 for GG+AG vs. AA), but it was associated with decreased risk of colorectal cancer (OR=0.59, 95% CI: 0.41-0.85, P=0.005 for GG+AG vs. AA). Subgroup analysis by ethnicity revealed a decreased risk of cancer among Caucasians (OR=0.88, 95% CI: 0.78-0.99, P=0.03 for GG+AG vs. AA)
conclusionThe evidence from current meta-analysis doesn't support the ICAM-1 +469 A/G polymorphism as a risk factor for cancer. Further studies are needed to validate these findings.
Indexed as
Identifiers
24482692PMC3902244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.